Association of Nutritional Indices With Adverse Effects and Time-to-Treatment-Failure in Triple Therapy for Lung Cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Prognostic Nutritional Index (PNI) predicts treatment success in non-small cell lung cancer patients receiving triple therapy. Low PNI indicates shorter time-to-treatment-failure, but does not predict immune-related side effects.
Area Of Science
- Oncology
- Immunotherapy
- Nutritional Science
Background
- Triple therapy combining immune checkpoint inhibitors (ICIs) like pembrolizumab with chemotherapy is a standard treatment for non-small cell lung cancer (NSCLC).
- Nutritional status, assessed by indices like Geriatric Nutritional Risk Index (GNRI) and Prognostic Nutritional Index (PNI), impacts cancer patient outcomes.
- Previous studies suggest PNI correlates with treatment response in NSCLC, but its role in triple therapy is not well-defined.
Purpose Of The Study
- To investigate the association between nutritional indices (GNRI and PNI) and treatment outcomes in NSCLC patients receiving pembrolizumab, platinum-based agents, and a cytotoxic agent.
- To determine if GNRI or PNI predicts time-to-treatment-failure (TTF) and immune-related adverse events (irAEs) in this patient cohort.
Main Methods
- A retrospective study of 72 NSCLC patients treated with carboplatin, pemetrexed, and pembrolizumab.
- Patients were categorized into High and Low groups based on baseline GNRI and PNI values.
- Statistical analyses, including Cox proportional hazards regression, were used to evaluate TTF and irAEs.
Main Results
- Low PNI was significantly associated with shorter TTF in both univariate and multivariate analyses (p=0.006 and p=0.005, respectively).
- PNI was identified as an independent prognostic factor for TTF (HR=2.791, 95%CI=1.362-5.721).
- GNRI did not show a significant association with TTF, and PNI was not a predictor of irAE development.
Conclusions
- Baseline PNI is an independent prognostic factor for treatment success, specifically time-to-treatment-failure, in NSCLC patients undergoing triple therapy.
- PNI does not appear to predict the occurrence of immune-related adverse events in this setting.
- Nutritional assessment using PNI may aid in predicting treatment duration and outcomes for NSCLC patients on combination immunotherapy and chemotherapy.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...